Markets:

Overview

News

Currencies

International

Treasuries

Merus N.V. - Common Shares (NQ:MRUS)

90.00 UNCHANGED

Last Price Updated: 4:00 PM EST, Dec 29, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Merus N.V. - Common Shares

< Previous 1 2 3 4 Next >

Let's take a look at the stocks that are in motion in today's session. ↗

May 23, 2025

Curious to know what's happening on the US markets in the middle of the day on Friday? Join us as we explore the top gainers and losers in today's session.

Via Chartmill

Merus Stock Soars On Positive Phase 2 Drug Trial Data, Price Target Hikes: Retail’s Thrilled ↗

May 23, 2025

BofA’s new price target of $92 implies a 121% upside to Merus’s closing share price of $41.6 on Thursday.

Via Stocktwits

Frontline, Merus, Intuit And Other Big Stocks Moving Higher On Friday ↗

May 23, 2025

Via Benzinga

There are notable gap-ups and gap-downs in today's session. ↗

May 23, 2025

Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Friday. Let's explore the market movements and identify the stocks with significant gaps.

Via Chartmill

What's Going On With Merus Stock Monday? ↗

January 13, 2025

Merus announced a research collaboration and license agreement with Biohaven.

Via Benzinga

Merus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara Therapeutics ↗

May 23, 2025

The companies are duking it out for the best treatment for head-and-neck cancer. One clearly has the edge.

Via Investor's Business Daily

Discover the top movers in Friday's pre-market session. ↗

May 23, 2025

As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.

Via Chartmill

Merus Shares Are Up Today: What's Going On? ↗

February 18, 2025

Shares of Merus N.V. (NASDAQ: MRUS) are trading higher Tuesday after the company announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) for...

Via Benzinga

This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

February 13, 2025

Via Benzinga

Expert Ratings for Merus ↗

November 28, 2023

Via Benzinga

The Latest Analyst Ratings for Merus ↗

October 24, 2023

Via Benzinga

10 Analysts Have This to Say About Merus ↗

September 14, 2023

Via Benzinga

TD Synnex, Walgreens, Savers Value Village And Other Big Stocks Moving Higher On Friday ↗

January 10, 2025

Via Benzinga

Merus Scores Its First FDA Approval For Lung Cancer Drug ↗

December 05, 2024

FDA approves Merus' Bizengri as the first treatment for advanced NRG1 fusion-positive cancers. U.S. peak sales are estimated at $16.5 million.

Via Benzinga

Jim Cramer: This Health Care Stock Is 'Very, Very Speculative' ↗

December 05, 2024

Jim Cramer called Allison Transmission a "storied company... terrific. It does great."

Via Benzinga

Merus Licenses US Commercialization Rights For Cancer Potential Zenocutuzumab, Analyst Highlight Merus' Pipeline ↗

December 02, 2024

Merus partners with Partner Therapeutics for U.S. rights to Zeno in NRG1+ cancer. Updated petosemtamab data emerge as a key focus for analysts.

Via Benzinga

XPeng, NovoCure, Merus, Gap And Other Big Stocks Moving Higher On Monday ↗

December 02, 2024

Via Benzinga

This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

November 21, 2024

Via Benzinga

MRUS Stock Earnings: Merus Misses EPS, Misses Revenue for Q2 2024 ↗

August 01, 2024

MRUS stock results show that Merus missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.

Via InvestorPlace

Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

May 28, 2024

Via Benzinga

Crude Oil Rises 1%; Verastem Shares Slide ↗

May 24, 2024

Via Benzinga

Why NetEase Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

May 24, 2024

Via Benzinga

Why Is Cancer-Focused Merus Stock Trading Over 30% On Friday? ↗

May 24, 2024

Merus announces interim clinical data on petosemtamab and Keytruda (pembrolizumab) for first-line recurrent/metastatic head and neck squamous cell carcinoma. Early results show promising efficacy with...

Via Benzinga

Nasdaq Gains 1%; Intuit Shares Plunge ↗

May 24, 2024

Via Benzinga

Why Top 4% Biotech Stock, Merus, Just Catapulted To A Record High ↗

May 24, 2024

The company passed investors' bar for success in a study of a head-and-neck cancer treatment.

Via Investor's Business Daily

Deckers Outdoor Posts Upbeat Earnings, Joins Guardant Health, Ross Stores And Other Big Stocks Moving Higher On Friday ↗

May 24, 2024

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

May 24, 2024

We're diving into the biggest pre-market stock movers that traders need to know about on Friday morning with all of the latest news!

Via InvestorPlace

MRUS Stock Earnings: Merus Beats EPS, Misses Revenue for Q1 2024 ↗

May 09, 2024

MRUS stock results show that Merus beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

Via InvestorPlace

AstraZeneca's Tagrisso-Chemo Combo Data In Lung Cancer Sets High Bar For Johnson & Johnson's Cancer Drug: Analyst ↗

September 11, 2023

On Sunday night, AstraZeneca Plc (NASDAQ: AZN) presented the Phase 3 FLAURA2 results evaluating Tagrisso plus chemotherapy versus Tagrisso monotherapy as first-line treatment for patients

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 21, 2023 ↗

August 21, 2023

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Merus N.V. - Common Shares (NQ:MRUS)

Headline News about Merus N.V. - Common Shares

Starting at $3.75/week.

Subscribe Today